Name (Synonyms) | Correlation | |
---|---|---|
drug1213 | Saliva collection Wiki | 0.71 |
drug136 | Azithromycin Tablets Wiki | 0.71 |
drug608 | Hydroxychloroquine Sulfate Wiki | 0.32 |
Name (Synonyms) | Correlation | |
---|---|---|
D055371 | Acute Lung Injury NIH | 0.12 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.12 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.10 |
D018352 | Coronavirus Infections NIH | 0.05 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Prospective, mono centric study on COVID-19 patients with or without acute respiratory distress syndrome (ARDS) to analyse the dynamics of the immune response and to search for biomarkers of evolution
Description: Blood sample
Measure: Number of increased immune population Time: Month 4Description: Blood sample
Measure: Number of decreased immune population Time: Month 4Description: Blood sample
Measure: Number of statically different phenotypes compared to control patients Time: Month 4Description: Qualitative identification of immune subpopulations showing a significant variation compared to controls and quantification of this variation (at D1 and/or D14)
Measure: Gain or loss of functional phenotypic markers between D1 and D14 Time: Day 14Description: Qualitative identification of immune subpopulations showing a significant variation between acute and mild COVID-19 and quantification of this variation (at D1 and/or D14)
Measure: Gain or loss of functional phenotypic markers between between acute and mild infections Time: Day 14Description: Qualitative identification of immune subpopulations showing a significant variation between acute stage and recovery (at 4 months) and quantification of this variation
Measure: Gain or loss of functional phenotypic markers between D1 and month 4 Time: Month 4Description: Blood sample
Measure: Evaluation of V, D, J gene usage alterations in the immunoglobulin and T cell receptor (TCR) repertoires during ARDS linked to COVID-19 Time: Day 14Description: Blood sample
Measure: Identification of the Ig classes and of V, D, J sequences of anti-CoV-2 antibodies Time: Month 4Description: Blood sample
Measure: Characterization of a new set of human antibodies from patients who have recovered of COVID-19 Time: Month 4